Neuromodulation in Patients With Neuropathic Pain and Depression.

Inclusion Criteria:

• Central or peripheral neuropathic pain

• Chronic pain (present for more than 6 months) with intensity greater than or equalto 4/10 on the numerical scale

• Pain present on a daily or near-daily basis (at least 4 days a week)

• Patient not completely relieved by recommended drug treatments for first- andsecond-line neuropathic pain

• Stable analgesic treatment (no new treatment or dosage adjustment) for at least onemonth, and will not need to be modified for the duration of the study.

• Patient with a depressive episode characterized according to DSM V criteria

• Indication for motor cortex rTMS by a neurologist

• Patient can be followed for the entire duration of the study

• Patient having received informed consent to participate in the study, and havingco-signed a consent form with the investigator

• Member or beneficiary of a social security scheme

Exclusion Criteria:

• Industrial accident or litigation

• Contraindication to rTMS or MRI (seismotherapy treatment since the previous month;epilepsy and/or history of epilepsy; history of head trauma; neurosurgical lesion;intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulinpump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia)

• Drug or psychoactive substance abuse

• Neuropathic pain in the context of a progressive pathology (HIV, cancer, systemicdisease disease)

• Presence of other pain more severe than that justifying inclusion

• Patient unable to understand informed consent

• Patient unwilling or unable to stop treatments prohibited during the study

• Patient participating in another research protocol involving a drug within the 30days prior to inclusion

• Patient deprived of liberty or under legal protection (guardianship, curatorship,safeguard of justice safeguard, family safeguard)

• Minor patient